Cord Blood News Volume 8.22 | Jun 9 2016

TOP STORY

Protective Mitochondrial Transfer from Bone Marrow Stromal Cells to Acute Myeloid Leukemic Cells during Chemotherapy

Scientists demonstrated that in a niche-like co-culture system, cells from both primary and cultured acute myeloid leukemia (AML) sources take up functional mitochondria from murine or human bone marrow stromal cells. Transfer was greater in AML blasts compared to normal cord blood CD34⁺ cells. [Blood] Abstract

(Ranked by impact factor of the journal)

Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies

To establish the safety and efficacy of human umbilical cord blood-derived mesenchymal stem cells in atopic dermatitis, thirty-four adult patients with moderate-to-severe atopic dermatitis were enrolled in two phase trials with a follow-up for one month and three months, respectively. [Stem Cells] Abstract | Press Release

Late Effects Following Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning

The authors describe the late effects in 102 consecutive patients surviving a minimum of five years (median follow-up 12.9 years) post cord blood transplantation. [Biol Blood Marrow Transplant] Abstract

A Novel TCR-Like CAR with Specificity for PR1/HLA-A2 Effectively Targets Myeloid Leukemia In Vitro when Expressed in Human Adult Peripheral Blood and Cord Blood T Cells

Adult human normal peripheral blood T cells were efficiently transduced with the h8F4-chimeric antigen receptor (CAR) construct and predominantly displayed an effector memory phenotype with a minor population of central memory cells in vitro. Umbilical cord blood T cells could also be efficiently transduced with the h8F4-CAR. [Cytotherapy] Abstract

High Quality Independent from a Donor: Human Amniotic Fluid Derived Stem Cells – A Practical Analysis Based on 165 Clinical Cases

Scientists revealed that mesenchymal stem cells could be derived successfully from amniotic fluid, which exhibit properties comparable with other origins. [J Cell Biochem] Abstract

Hyaluronic Acid Enhances Proliferation of Human Amniotic Mesenchymal Stem Cells through Activation of Wnt/β-Catenin Signaling Pathway

The authors investigated the pro-proliferative effect of hyaluronic acid on human amniotic mesenchymal stem cells and the underlying mechanisms. [Exp Cell Res] Abstract

A Comparative Study of Growth Kinetics, In Vitro Differentiation Potential and Molecular Characterization of Fetal Adnexa Derived Caprine Mesenchymal Stem Cells

Scientists revealed that Wharton’s jelly mesenchymal stem cells (MSCs) outperformed MSCs from other sources of fetal adnexa in terms of growth kinetics, relative mRNA expression of surface antigens, pluripotency markers and tri-lineage differentiation potential [PLoS One] Full Article

Association of Expression Levels of Pluripotency/Stem Cell Markers with the Differentiation Outcome of Wharton’s Jelly Mesenchymal Stem Cells into Insulin Producing Cells

Researchers investigated the levels of pluripotency/stem cell markers during differentiation of Wharton’s jelly mesenchymal stem cells into insulin producing cells and the association of these levels with differentiation outcomes. [Biochimie] Abstract

Wilms Tumor 1 Mutations in the Pathogenesis of Acute Myeloid Leukemia

New evidence has emerged that points towards a novel role of Wilms tumor 1 mutations in the deregulation of epigenetic programs in leukemic cells through its interaction with TET proteins.The authors review the current status of the field and its therapeutic and prognostic implications in acute myeloid leukemia. [Haematologica] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Americord Announces Increasing Stem Cell Yields, Including Record Collection

Americord announced that it has reached several milestones, including record cord blood collection volumes and record yields of total nucleated cell counts. [Americord] Press Release

Kiadis Pharma Announces Its Decision to File for Marketing Authorization with the European Medicines Agency (EMA) for ATIR101™ in Blood Cancers

Kiadis Pharma N.V. announced a regulatory strategy update that, based on positive Phase II data, it has taken the decision to submit a marketing authorization application to the EMA for its lead product ATIR101™ for use in blood cancers to reduce relapse rates, transplant related mortality and graft-versus-host-disease in the context of a hematopoietic stem cell transplantation using a haploidentical donor. [Kiadis Pharma N.V.] Press Release

NEW 15^th International Congress on Antiphospholipid Antibodies
September 21-24, 2016
Istanbul, Turkey

Visit our events page to see a complete list of events in the cord blood community.

NEW Postdoctoral Research Position – Pediatric Hematology and Oncology (Hannover Medical School)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Technical Sales Representative (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Targeting the Bone Marrow Microenvironment for Drug Resistant AML (NUI Galway)

Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Positions – Stem Cell Biology and Regenerative Medicine (University of Southern California)

Postdoctoral Research Associate – TAM-Family Kinases in Leukemogenesis (Emory University)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.